Legend Biotech (LEGN) Amortization of Deferred Charges (2020 - 2026)

Legend Biotech (LEGN) has 6 years of Amortization of Deferred Charges data on file, last reported at $4.0 million in Q3 2025.

• Quarterly Amortization of Deferred Charges rose 42.64% year-over-year to $4.0 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $13.0 million (up 43.79% YoY) and the FY2022 annual result came in at $5.7 million, up 30.55% from the prior year.
• Amortization of Deferred Charges grew to $4.0 million in Q3 2025, from $3.5 million in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $5.7 million in Q4 2022 to a low of $257000.0 in Q1 2022.
• A 5-year average of $2.2 million and a median of $2.2 million in 2024 frame the typical range for Amortization of Deferred Charges.
• The widest YoY moves for Amortization of Deferred Charges: up 525.21% in 2022, down 29.4% in 2022.
• Tracing LEGN's Amortization of Deferred Charges over 5 years: stood at $4.4 million in 2021, then soared by 30.55% to $5.7 million in 2022, then tumbled by 65.23% to $2.0 million in 2023, then soared by 39.06% to $2.8 million in 2024, then surged by 42.64% to $4.0 million in 2025.
• The last three Amortization of Deferred Charges figures came in at $4.0 million (Q3 2025), $3.5 million (Q2 2025), and $2.8 million (Q1 2025), per Business Quant data.